A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)

Protocol No
RHEU-PROMETHEUS-ATHENA
Phase
II
Summary

This project is being done to find out whether an investigational drug for systemic sclerosis associated with interstitial lung disease (SScILD), PRA023, is better than placebo.

Description
PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (ATHENA-SSc-ILD)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Lungs and Breathing, ILD/IPF
ClinicalTrials.gov
go to website